iOnctura is a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers with precision oral small molecules that target cancers in novel ways. The bold new treatments extend lives and improve healthspans, changing the outlook for patients and their families.
Products, services, technology
Roginolisib: an allosteric modulator of PI3Kδ. Cambritaxestat: a novel autotaxin (ATX) inhibitor. iOnctura also has an early pipeline of antibody candidates.
Cooperation possibilities
We innovate, through pioneering scientific research, in collaboration with world renowned collaborators to develop selective therapies against targets of interest to us.
